Everand Logo

Welcome to Everand!

  • STAT

    Grail, the liquid biopsy startup, picks an approach for its cancer test

    Grail, the company that has raised $1.6 billion to develop a blood test to detect cancer early, announced that it has settled on a method for its test.
    by Matthew Herper May 13, 2019 1 minute

    Grail, the company that has raised $1.6 billion to , announced Monday that it has settled on a method for its test and enrolled 115,000 patients in two large clinical trials.

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min readCrime & Violence
    STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
    A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.
    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
    An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.

    Related Books & Audiobooks